SynthesisFrontiers in microbiology2025
Global prevalence and antibiotic resistance profiles of carbapenem-resistant
Synthesis in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- "One Health" perspective on the prevalence of Listeria monocytogenes and its antibiotic resistance profiles in South Africa: a comprehensive systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Isolation and characterization of bacteriophages against antibiotic-resistanceIranian journal of microbiology · 2026Article
- Occurrence and Distribution of Environmental Pseudomonas aeruginosa From Hospitals in Bangladesh Reveals Diverse Strain Families, Multidrug Resistance, and Biofilm Formation.Environmental microbiology reports · 2026Article
- Inhibition of Quorum Sensing-Controlled Virulence Factors and Biofilm inAntibiotics (Basel, Switzerland) · 2026Article
- Characterization of Nasopharyngeal Microbiota Dysbiosis in Children withMicroorganisms · 2026Article
- Increased Carbapenem resistance and gene carriage in Pseudomonas aeruginosa clinical isolates after the COVID-19 pandemic in Egypt.Molecular biology reports · 2026Article
- Characterization of the Fiber Protein C-Terminal Domain fromInternational journal of molecular sciences · 2026Article
- Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies.Archives of microbiology · 2026Review
- Genomic characterization of Pseudomonas aeruginosa clonal lineage ST162 isolated from bovine-milk in South Africa.BMC microbiology · 2026Article
- Review
- Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.Diagnostics (Basel, Switzerland) · 2026Review
- Clinical distribution and drug resistance of carbapenem-resistant Pseudomonas aeruginosa infection in Eastern China from 2019 to 2024.BMC infectious diseases · 2026Article
- Chamomile oil and apigenin as novel modulators of mexA, mexB, mexR, and oprM efflux pump genes in multidrug-resistant Pseudomonas aeruginosa.One health outlook · 2026Article
- Molecular characteristics of chromosome-mediated colistin resistance in carbapenem-resistant Pseudomonas aeruginosa isolates from a tertiary hospital in China.BMC microbiology · 2026Article
- Antimicrobial and anti-virulent efficacies of melanin, and risk factors associated withFrontiers in cellular and infection microbiology · 2026Article
- Antimicrobial susceptibility patterns in Jalisco, Mexico: a snapshot of regional resistance (2021-2023).Frontiers in cellular and infection microbiology · 2026Article
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Genomics in Epidemiology and Disease Surveillance: An Exploratory Analysis.Life (Basel, Switzerland) · 2025Review
- The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study.Antibiotics (Basel, Switzerland) · 2025Article
- Rapid On-Site Detection ofBiosensors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Carbapenem-resistant Methods: We conducted a systematic review and meta-analysis on the global pooled prevalence estimate (PPE) of CRPA and their antibiotic resistance. The systematic review protocol was registered with PROSPERO (CRD42024579654). This study was carried out following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Heterogeneity between studies was assessed using Cochrane Q test and I Results: A total of 163 studies (both clinical and screening samples) containing a total of 58,344 cases from 39 countries were included in this study. The overall PPE of CRPA was 34.7% (95% CI: 0.316-0.37.8) for both clinical and screening samples. Meropenem had a PPE of 31.2% (95% CI: 0.272-0.352) and imipenem had the lowest PPE of 27.7% (95% CI: 0.238-0.319). Japan had the highest PPE at 98.2% (95% CI: 0.482-0.100) of CRPA, and the lowest was observed for Saudi Arabia at 13.9% (95% CI: 0. 064-0. 277). CRPA is widespread on five continents except Australia and Antarctica, while the highest PPE is in Europe at 47.6% (95% CI: 0.359-0.595) and the lowest in Asia at 32, 8% (95% CI: 0.293-0.364). The relatively higher PPE of CRPA was observed in Europe during the year interval 2014-2017 at 95.4% (95% CI: 0.388-0.999), followed by Africa from the year 2022-2024 with 38.5% (95% CI: 0.243-0.550). Ceftazidime was significantly higher in studies conducted before 2019 with a PPE of 44.7% (95% CI: 0.246% - 0.668), while CRPA after 2019 had a higher resistance to cefoperazone/sulbactam with a PPE of 17.3% (95% CI: 0.050-0.455). Discussion: This review indicates that the prevalence of CRPA is generally high and varies significantly between countries. To prevent the emergence of CRPA and antibiotic resistance, future initiatives should prioritise strengthening laboratory capacity for early detection of antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.